Belpointe Asset Management LLC Acquires 412 Shares of Zoetis Inc. (NYSE:ZTS)

Belpointe Asset Management LLC raised its stake in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 24.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,071 shares of the company’s stock after purchasing an additional 412 shares during the period. Belpointe Asset Management LLC’s holdings in Zoetis were worth $409,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Blue Bell Private Wealth Management LLC grew its holdings in Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares in the last quarter. Independence Bank of Kentucky raised its holdings in shares of Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Private Wealth Management Group LLC purchased a new position in shares of Zoetis during the 4th quarter valued at $33,000. Ramirez Asset Management Inc. bought a new position in shares of Zoetis during the 3rd quarter worth $35,000. Finally, Gladius Capital Management LP bought a new stake in Zoetis in the 4th quarter valued at about $40,000. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Up 0.5 %

Shares of ZTS opened at $176.78 on Friday. The firm has a market cap of $80.66 billion, a P/E ratio of 34.06, a P/E/G ratio of 2.73 and a beta of 0.88. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The stock has a 50 day simple moving average of $164.62 and a two-hundred day simple moving average of $179.64.

Zoetis (NYSE:ZTSGet Free Report) last issued its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.04. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The company had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. During the same period in the prior year, the business posted $1.31 EPS. Zoetis’s quarterly revenue was up 9.5% compared to the same quarter last year. On average, analysts forecast that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the sale, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at $2,237,316. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on ZTS. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Piper Sandler reiterated an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Stifel Nicolaus reduced their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. HSBC lowered their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Finally, Barclays decreased their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $211.75.

Read Our Latest Research Report on Zoetis

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Read More

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.